Table 2:
Association of VEGF-C, VEGFR1 (FLT1), and VEGFR3 (FLT4) mRNA expression with clinicopathological parameters.
VEGF-C
VEGFR1 (FLT1)
VEGFR3 (FLT4)
Low
High
Low
High
Low
High
Alcohol consumption
.168
.324
.999
Low
4 (20)
9 (45)
8 (40)
5 (25)
7 (35)
6 (32)
Moderate
10 (50)
5 (25)
5 (25)
10 (50)
8 (40)
7 (37)
High
6 (30)
6 (30)
7 (35)
5 (25)
5 (25)
6 (32)
Site of relapse
.009
.056
.017
Local only
17 (85)
10 (50)
17 (85)
10 (50)
18 (90)
9 (47)
Lymph nodes ± Local
3 (19)
3 (15)
2 (10)
4 (20)
1 (5)
5 (26)
Other
0 (0)
7 (35)
1 (5)
6 (30)
1 (5)
5 (26)
Size at 1st relapse
.712
.110
.999
<2 cm
3 (15)
4 (20)
6 (30)
1 (5)
4 (20)
3 (16)
2–4 cm
10 (50)
9 (45)
11 (55)
10 (50)
11 (55)
9 (47)
>4 cm
5 (25)
2 (10)
2 (10)
5 (25)
4 (20)
3 (16)
Unknown
2(10)
5 (25)
1 (5)
4 (20)
1 (5)
4 (21)
Lymph nodes at diagnosis
.342
.047
.041
N0
19 (95)
16 (80)
20 (100)
15 (75)
20 (100)
14 (74)
N1-N2
1 (5)
3 (15)
0 (0)
4 (20)
0 (0)
4 (21)
Unknown
0 (0)
1 (5)
0 (0)
1 (5)
0 (0)
1 (5)
Differentiation grade at relapse
.697
.697
.697
Well or moderate
14 (70)
10 (50)
14 (70)
10 (50)
14 (70)
10 (53)
Poor or undifferentiated
4 (20
5 (25)
4 (20)
5 (25)
4 (20)
5 (26)
Unknown
2 (10)
5 (25)
2 (10)
5 (25)
2 (10)
4 (21)
Pack years exposure
.341
.341
.751
<52.5
9 (45)
13 (65)
9 (45)
13 (65)
10 (50)
11 (58)
>52.5
11 (55)
7 (35)
11 (55)
7 (35)
10 (50)
8 (42)
Age
.527
.999
.999
<65
9 (45)
12 (60)
11 (55)
10 (50)
10 (50)
10 (53)
>65
11 (55)
8 (40)
9 (45)
10 (50)
10 (50)
9 (47)
Diagnosis to recurrence interval
.333
.748
.748
<12 months
6 (30)
10 (50)
7 (35)
9 (45)
9 (45)
7 (37)
>12 months
14 (70)
10 (50)
13 (65)
11 (55)
11 (55)
12 (63)